Table 1

Impact of P-gp on transcellular transport of talinolol in LLC-PK1/MDR1, LLC-PK1/Mdr1a, LLC-PK1/Mdr1b, and LLC-PK1/mock cells

Cell LinesTalinololaPappRatioc
AP to BLBL to AP
×106 cm/s
LLC-PK1/MDR1Alone1.48 ± 0.044.01 ± 0.032.71 ± 0.02*
+ Cyclosporine Ab3.07 ± 0.082.02 ± 0.080.66 ± 0.02†
LLC-PK1/Mdr1aAlone1.21 ± 0.022.24 ± 0.131.86 ± 0.11*
+ Cyclosporine Ab1.98 ± 0.051.43 ± 0.120.72 ± 0.06†
LLC-PK1/Mdr1bAlone1.62 ± 0.053.33 ± 0.252.05 ± 0.15*
LLC-PK1/mockAlone1.31 ± 0.021.76 ± 0.021.34 ± 0.02
  • * P < 0.05, significantly different from permeability ratio in LLC-PK1/mock cells; † P < 0.05, significantly different from permeability ratio in the absence of cyclosporine A.

  • a Initial donor concentration of talinolol was 10 μM.

  • b Applied concentration of cyclosporine A was 10 μM.

  • c The permeability ratio (BL to AP/AP to BL). Data are represented as the mean ± S.E.M. (n = 3).